nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—SLC22A5—Dactinomycin—kidney cancer	0.314	1	CbGbCtD
Ceftazidime—SLC22A5—Temsirolimus—Everolimus—kidney cancer	0.0143	1	CbGdCrCtD
Ceftazidime—SLC22A6—nephron tubule—kidney cancer	0.00499	0.124	CbGeAlD
Ceftazidime—SLC22A6—cortex of kidney—kidney cancer	0.00427	0.106	CbGeAlD
Ceftazidime—SLC15A1—nephron tubule—kidney cancer	0.00415	0.103	CbGeAlD
Ceftazidime—SLC15A1—renal system—kidney cancer	0.00377	0.0935	CbGeAlD
Ceftazidime—SLC15A1—kidney—kidney cancer	0.00365	0.0904	CbGeAlD
Ceftazidime—SLC15A2—nephron tubule—kidney cancer	0.0026	0.0643	CbGeAlD
Ceftazidime—SLC15A2—renal system—kidney cancer	0.00236	0.0585	CbGeAlD
Ceftazidime—SLC15A2—kidney—kidney cancer	0.00228	0.0565	CbGeAlD
Ceftazidime—SLC22A5—nephron tubule—kidney cancer	0.00226	0.0559	CbGeAlD
Ceftazidime—SLC15A2—cortex of kidney—kidney cancer	0.00222	0.055	CbGeAlD
Ceftazidime—SLC22A5—renal system—kidney cancer	0.00205	0.0508	CbGeAlD
Ceftazidime—SLC22A5—kidney—kidney cancer	0.00198	0.0492	CbGeAlD
Ceftazidime—SLC22A5—cortex of kidney—kidney cancer	0.00193	0.0479	CbGeAlD
Ceftazidime—SLC22A5—cardiac atrium—kidney cancer	0.00184	0.0455	CbGeAlD
Ceftazidime—Thrombocytopenia—Sunitinib—kidney cancer	0.000935	0.00148	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Everolimus—kidney cancer	0.000934	0.00148	CcSEcCtD
Ceftazidime—Skin disorder—Sunitinib—kidney cancer	0.000927	0.00147	CcSEcCtD
Ceftazidime—Vomiting—Pazopanib—kidney cancer	0.00092	0.00146	CcSEcCtD
Ceftazidime—Colitis—Doxorubicin—kidney cancer	0.000913	0.00145	CcSEcCtD
Ceftazidime—Rash—Pazopanib—kidney cancer	0.000913	0.00145	CcSEcCtD
Ceftazidime—Nausea—Temsirolimus—kidney cancer	0.000913	0.00145	CcSEcCtD
Ceftazidime—Dermatitis—Pazopanib—kidney cancer	0.000912	0.00144	CcSEcCtD
Ceftazidime—Bronchospasm—Capecitabine—kidney cancer	0.00091	0.00144	CcSEcCtD
Ceftazidime—Agitation—Vincristine—kidney cancer	0.000909	0.00144	CcSEcCtD
Ceftazidime—Skin exfoliation—Doxorubicin—kidney cancer	0.000908	0.00144	CcSEcCtD
Ceftazidime—Candida infection—Doxorubicin—kidney cancer	0.000908	0.00144	CcSEcCtD
Ceftazidime—Haemoglobin—Paclitaxel—kidney cancer	0.000907	0.00144	CcSEcCtD
Ceftazidime—Abdominal pain—Vinblastine—kidney cancer	0.000907	0.00144	CcSEcCtD
Ceftazidime—Headache—Pazopanib—kidney cancer	0.000907	0.00144	CcSEcCtD
Ceftazidime—Abdominal pain—Everolimus—kidney cancer	0.000903	0.00143	CcSEcCtD
Ceftazidime—Body temperature increased—Everolimus—kidney cancer	0.000903	0.00143	CcSEcCtD
Ceftazidime—Haemorrhage—Paclitaxel—kidney cancer	0.000903	0.00143	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Erlotinib—kidney cancer	0.000902	0.00143	CcSEcCtD
Ceftazidime—Vaginal infection—Doxorubicin—kidney cancer	0.000898	0.00142	CcSEcCtD
Ceftazidime—Aplastic anaemia—Doxorubicin—kidney cancer	0.000893	0.00141	CcSEcCtD
Ceftazidime—Leukopenia—Vincristine—kidney cancer	0.000885	0.0014	CcSEcCtD
Ceftazidime—Thrombocytopenia—Dactinomycin—kidney cancer	0.000885	0.0014	CcSEcCtD
Ceftazidime—Pancytopenia—Capecitabine—kidney cancer	0.000879	0.00139	CcSEcCtD
Ceftazidime—Body temperature increased—Erlotinib—kidney cancer	0.000872	0.00138	CcSEcCtD
Ceftazidime—Abdominal pain—Erlotinib—kidney cancer	0.000872	0.00138	CcSEcCtD
Ceftazidime—Coma—Doxorubicin—kidney cancer	0.000869	0.00138	CcSEcCtD
Ceftazidime—Neutropenia—Capecitabine—kidney cancer	0.000865	0.00137	CcSEcCtD
Ceftazidime—Nausea—Pazopanib—kidney cancer	0.00086	0.00136	CcSEcCtD
Ceftazidime—Paraesthesia—Sunitinib—kidney cancer	0.000857	0.00136	CcSEcCtD
Ceftazidime—Convulsion—Vincristine—kidney cancer	0.000857	0.00136	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000856	0.00136	CcSEcCtD
Ceftazidime—Erythema multiforme—Paclitaxel—kidney cancer	0.000853	0.00135	CcSEcCtD
Ceftazidime—Pain—Sorafenib—kidney cancer	0.000848	0.00134	CcSEcCtD
Ceftazidime—Hypersensitivity—Vinblastine—kidney cancer	0.000845	0.00134	CcSEcCtD
Ceftazidime—Hypersensitivity—Everolimus—kidney cancer	0.000842	0.00133	CcSEcCtD
Ceftazidime—Leukopenia—Gemcitabine—kidney cancer	0.00084	0.00133	CcSEcCtD
Ceftazidime—Flushing—Paclitaxel—kidney cancer	0.000838	0.00133	CcSEcCtD
Ceftazidime—Infestation—Capecitabine—kidney cancer	0.000825	0.00131	CcSEcCtD
Ceftazidime—Infestation NOS—Capecitabine—kidney cancer	0.000825	0.00131	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000824	0.00131	CcSEcCtD
Ceftazidime—Angiopathy—Paclitaxel—kidney cancer	0.000819	0.0013	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.000818	0.0013	CcSEcCtD
Ceftazidime—Pain—Sunitinib—kidney cancer	0.000816	0.00129	CcSEcCtD
Ceftazidime—Immune system disorder—Paclitaxel—kidney cancer	0.000815	0.00129	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Sorafenib—kidney cancer	0.000811	0.00128	CcSEcCtD
Ceftazidime—Renal failure—Capecitabine—kidney cancer	0.000811	0.00128	CcSEcCtD
Ceftazidime—Pruritus—Everolimus—kidney cancer	0.000808	0.00128	CcSEcCtD
Ceftazidime—Anaphylactic shock—Vincristine—kidney cancer	0.000807	0.00128	CcSEcCtD
Ceftazidime—Jaundice—Capecitabine—kidney cancer	0.000804	0.00127	CcSEcCtD
Ceftazidime—Phlebitis—Doxorubicin—kidney cancer	0.000801	0.00127	CcSEcCtD
Ceftazidime—Thrombophlebitis—Doxorubicin—kidney cancer	0.000797	0.00126	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000793	0.00126	CcSEcCtD
Ceftazidime—Nervous system disorder—Vincristine—kidney cancer	0.000792	0.00125	CcSEcCtD
Ceftazidime—Thrombocytopenia—Vincristine—kidney cancer	0.00079	0.00125	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Doxorubicin—kidney cancer	0.00079	0.00125	CcSEcCtD
Ceftazidime—Urticaria—Sorafenib—kidney cancer	0.000788	0.00125	CcSEcCtD
Ceftazidime—Diarrhoea—Vinblastine—kidney cancer	0.000785	0.00124	CcSEcCtD
Ceftazidime—Body temperature increased—Sorafenib—kidney cancer	0.000784	0.00124	CcSEcCtD
Ceftazidime—Abdominal pain—Sorafenib—kidney cancer	0.000784	0.00124	CcSEcCtD
Ceftazidime—Diarrhoea—Everolimus—kidney cancer	0.000782	0.00124	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Sunitinib—kidney cancer	0.000781	0.00124	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Capecitabine—kidney cancer	0.00078	0.00124	CcSEcCtD
Ceftazidime—Pruritus—Erlotinib—kidney cancer	0.00078	0.00124	CcSEcCtD
Ceftazidime—Pain—Dactinomycin—kidney cancer	0.000773	0.00122	CcSEcCtD
Ceftazidime—Agranulocytosis—Capecitabine—kidney cancer	0.00077	0.00122	CcSEcCtD
Ceftazidime—Dysgeusia—Paclitaxel—kidney cancer	0.000769	0.00122	CcSEcCtD
Ceftazidime—Anaphylactic shock—Gemcitabine—kidney cancer	0.000766	0.00121	CcSEcCtD
Ceftazidime—Dizziness—Vinblastine—kidney cancer	0.000759	0.0012	CcSEcCtD
Ceftazidime—Dizziness—Everolimus—kidney cancer	0.000756	0.0012	CcSEcCtD
Ceftazidime—Body temperature increased—Sunitinib—kidney cancer	0.000755	0.0012	CcSEcCtD
Ceftazidime—Abdominal pain—Sunitinib—kidney cancer	0.000755	0.0012	CcSEcCtD
Ceftazidime—Diarrhoea—Erlotinib—kidney cancer	0.000754	0.00119	CcSEcCtD
Ceftazidime—Hypotension—Vincristine—kidney cancer	0.000754	0.00119	CcSEcCtD
Ceftazidime—Nervous system disorder—Gemcitabine—kidney cancer	0.000751	0.00119	CcSEcCtD
Ceftazidime—Thrombocytopenia—Gemcitabine—kidney cancer	0.00075	0.00119	CcSEcCtD
Ceftazidime—Haemoglobin—Capecitabine—kidney cancer	0.000744	0.00118	CcSEcCtD
Ceftazidime—Skin disorder—Gemcitabine—kidney cancer	0.000744	0.00118	CcSEcCtD
Ceftazidime—Haemorrhage—Capecitabine—kidney cancer	0.000741	0.00117	CcSEcCtD
Ceftazidime—Vision blurred—Paclitaxel—kidney cancer	0.00074	0.00117	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000739	0.00117	CcSEcCtD
Ceftazidime—Hot flush—Doxorubicin—kidney cancer	0.000738	0.00117	CcSEcCtD
Ceftazidime—Tremor—Paclitaxel—kidney cancer	0.000736	0.00117	CcSEcCtD
Ceftazidime—Menopausal symptoms—Doxorubicin—kidney cancer	0.000731	0.00116	CcSEcCtD
Ceftazidime—Hypersensitivity—Sorafenib—kidney cancer	0.000731	0.00116	CcSEcCtD
Ceftazidime—Vomiting—Vinblastine—kidney cancer	0.000729	0.00116	CcSEcCtD
Ceftazidime—Dizziness—Erlotinib—kidney cancer	0.000729	0.00115	CcSEcCtD
Ceftazidime—Vomiting—Everolimus—kidney cancer	0.000727	0.00115	CcSEcCtD
Ceftazidime—Renal impairment—Doxorubicin—kidney cancer	0.000725	0.00115	CcSEcCtD
Ceftazidime—Paraesthesia—Vincristine—kidney cancer	0.000725	0.00115	CcSEcCtD
Ceftazidime—Agitation—Paclitaxel—kidney cancer	0.000722	0.00114	CcSEcCtD
Ceftazidime—Rash—Everolimus—kidney cancer	0.000721	0.00114	CcSEcCtD
Ceftazidime—Dermatitis—Everolimus—kidney cancer	0.00072	0.00114	CcSEcCtD
Ceftazidime—Headache—Vinblastine—kidney cancer	0.000719	0.00114	CcSEcCtD
Ceftazidime—Angioedema—Paclitaxel—kidney cancer	0.000718	0.00114	CcSEcCtD
Ceftazidime—Headache—Everolimus—kidney cancer	0.000716	0.00113	CcSEcCtD
Ceftazidime—Hypotension—Gemcitabine—kidney cancer	0.000716	0.00113	CcSEcCtD
Ceftazidime—Abdominal pain—Dactinomycin—kidney cancer	0.000714	0.00113	CcSEcCtD
Ceftazidime—Body temperature increased—Dactinomycin—kidney cancer	0.000714	0.00113	CcSEcCtD
Ceftazidime—Lethargy—Doxorubicin—kidney cancer	0.000704	0.00112	CcSEcCtD
Ceftazidime—Leukopenia—Paclitaxel—kidney cancer	0.000703	0.00111	CcSEcCtD
Ceftazidime—Hypersensitivity—Sunitinib—kidney cancer	0.000703	0.00111	CcSEcCtD
Ceftazidime—Pruritus—Sorafenib—kidney cancer	0.000702	0.00111	CcSEcCtD
Ceftazidime—Vomiting—Erlotinib—kidney cancer	0.000701	0.00111	CcSEcCtD
Ceftazidime—Erythema multiforme—Capecitabine—kidney cancer	0.0007	0.00111	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Vincristine—kidney cancer	0.000697	0.0011	CcSEcCtD
Ceftazidime—Rash—Erlotinib—kidney cancer	0.000695	0.0011	CcSEcCtD
Ceftazidime—Dermatitis—Erlotinib—kidney cancer	0.000695	0.0011	CcSEcCtD
Ceftazidime—Headache—Erlotinib—kidney cancer	0.000691	0.00109	CcSEcCtD
Ceftazidime—Pain—Vincristine—kidney cancer	0.00069	0.00109	CcSEcCtD
Ceftazidime—Paraesthesia—Gemcitabine—kidney cancer	0.000688	0.00109	CcSEcCtD
Ceftazidime—Flushing—Capecitabine—kidney cancer	0.000687	0.00109	CcSEcCtD
Ceftazidime—Nausea—Vinblastine—kidney cancer	0.000681	0.00108	CcSEcCtD
Ceftazidime—Convulsion—Paclitaxel—kidney cancer	0.000681	0.00108	CcSEcCtD
Ceftazidime—Nausea—Everolimus—kidney cancer	0.000679	0.00108	CcSEcCtD
Ceftazidime—Diarrhoea—Sorafenib—kidney cancer	0.000679	0.00108	CcSEcCtD
Ceftazidime—Pruritus—Sunitinib—kidney cancer	0.000675	0.00107	CcSEcCtD
Ceftazidime—Angiopathy—Capecitabine—kidney cancer	0.000672	0.00106	CcSEcCtD
Ceftazidime—Immune system disorder—Capecitabine—kidney cancer	0.000669	0.00106	CcSEcCtD
Ceftazidime—Hypersensitivity—Dactinomycin—kidney cancer	0.000666	0.00105	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000664	0.00105	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000661	0.00105	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Vincristine—kidney cancer	0.00066	0.00105	CcSEcCtD
Ceftazidime—Dizziness—Sorafenib—kidney cancer	0.000656	0.00104	CcSEcCtD
Ceftazidime—Pain—Gemcitabine—kidney cancer	0.000655	0.00104	CcSEcCtD
Ceftazidime—Nausea—Erlotinib—kidney cancer	0.000655	0.00104	CcSEcCtD
Ceftazidime—Diarrhoea—Sunitinib—kidney cancer	0.000653	0.00103	CcSEcCtD
Ceftazidime—Anaphylactic shock—Paclitaxel—kidney cancer	0.000641	0.00102	CcSEcCtD
Ceftazidime—Body temperature increased—Vincristine—kidney cancer	0.000638	0.00101	CcSEcCtD
Ceftazidime—Abdominal pain—Vincristine—kidney cancer	0.000638	0.00101	CcSEcCtD
Ceftazidime—Dysgeusia—Capecitabine—kidney cancer	0.000631	0.001	CcSEcCtD
Ceftazidime—Dizziness—Sunitinib—kidney cancer	0.000631	0.001	CcSEcCtD
Ceftazidime—Vomiting—Sorafenib—kidney cancer	0.000631	0.000999	CcSEcCtD
Ceftazidime—Nervous system disorder—Paclitaxel—kidney cancer	0.000629	0.000996	CcSEcCtD
Ceftazidime—Thrombocytopenia—Paclitaxel—kidney cancer	0.000628	0.000994	CcSEcCtD
Ceftazidime—Rash—Sorafenib—kidney cancer	0.000625	0.000991	CcSEcCtD
Ceftazidime—Dermatitis—Sorafenib—kidney cancer	0.000625	0.00099	CcSEcCtD
Ceftazidime—Skin disorder—Paclitaxel—kidney cancer	0.000623	0.000987	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000621	0.000984	CcSEcCtD
Ceftazidime—Headache—Sorafenib—kidney cancer	0.000621	0.000984	CcSEcCtD
Ceftazidime—Diarrhoea—Dactinomycin—kidney cancer	0.000618	0.000979	CcSEcCtD
Ceftazidime—Vision blurred—Capecitabine—kidney cancer	0.000608	0.000962	CcSEcCtD
Ceftazidime—Vomiting—Sunitinib—kidney cancer	0.000607	0.000961	CcSEcCtD
Ceftazidime—Body temperature increased—Gemcitabine—kidney cancer	0.000605	0.000959	CcSEcCtD
Ceftazidime—Tremor—Capecitabine—kidney cancer	0.000604	0.000957	CcSEcCtD
Ceftazidime—Rash—Sunitinib—kidney cancer	0.000602	0.000953	CcSEcCtD
Ceftazidime—Dermatitis—Sunitinib—kidney cancer	0.000601	0.000952	CcSEcCtD
Ceftazidime—Hypotension—Paclitaxel—kidney cancer	0.000599	0.000949	CcSEcCtD
Ceftazidime—Headache—Sunitinib—kidney cancer	0.000598	0.000947	CcSEcCtD
Ceftazidime—Hypersensitivity—Vincristine—kidney cancer	0.000595	0.000942	CcSEcCtD
Ceftazidime—Eosinophilia—Doxorubicin—kidney cancer	0.000591	0.000935	CcSEcCtD
Ceftazidime—Nausea—Sorafenib—kidney cancer	0.000589	0.000933	CcSEcCtD
Ceftazidime—Leukopenia—Capecitabine—kidney cancer	0.000577	0.000914	CcSEcCtD
Ceftazidime—Paraesthesia—Paclitaxel—kidney cancer	0.000576	0.000912	CcSEcCtD
Ceftazidime—Vomiting—Dactinomycin—kidney cancer	0.000575	0.00091	CcSEcCtD
Ceftazidime—Rash—Dactinomycin—kidney cancer	0.00057	0.000902	CcSEcCtD
Ceftazidime—Nausea—Sunitinib—kidney cancer	0.000567	0.000898	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—kidney cancer	0.000566	0.000897	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—kidney cancer	0.000558	0.000883	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000554	0.000877	CcSEcCtD
Ceftazidime—Diarrhoea—Vincristine—kidney cancer	0.000552	0.000875	CcSEcCtD
Ceftazidime—Pain—Paclitaxel—kidney cancer	0.000548	0.000869	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000545	0.000863	CcSEcCtD
Ceftazidime—Pruritus—Gemcitabine—kidney cancer	0.000542	0.000858	CcSEcCtD
Ceftazidime—Nausea—Dactinomycin—kidney cancer	0.000537	0.00085	CcSEcCtD
Ceftazidime—Dizziness—Vincristine—kidney cancer	0.000534	0.000846	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—kidney cancer	0.000532	0.000842	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—kidney cancer	0.000532	0.000842	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000527	0.000835	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000524	0.000831	CcSEcCtD
Ceftazidime—Diarrhoea—Gemcitabine—kidney cancer	0.000524	0.00083	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—kidney cancer	0.000523	0.000828	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—kidney cancer	0.000518	0.000821	CcSEcCtD
Ceftazidime—Nervous system disorder—Capecitabine—kidney cancer	0.000516	0.000817	CcSEcCtD
Ceftazidime—Thrombocytopenia—Capecitabine—kidney cancer	0.000515	0.000816	CcSEcCtD
Ceftazidime—Vomiting—Vincristine—kidney cancer	0.000513	0.000813	CcSEcCtD
Ceftazidime—Skin disorder—Capecitabine—kidney cancer	0.000511	0.00081	CcSEcCtD
Ceftazidime—Urticaria—Paclitaxel—kidney cancer	0.000509	0.000807	CcSEcCtD
Ceftazidime—Rash—Vincristine—kidney cancer	0.000509	0.000806	CcSEcCtD
Ceftazidime—Dermatitis—Vincristine—kidney cancer	0.000509	0.000806	CcSEcCtD
Ceftazidime—Abdominal pain—Paclitaxel—kidney cancer	0.000507	0.000803	CcSEcCtD
Ceftazidime—Body temperature increased—Paclitaxel—kidney cancer	0.000507	0.000803	CcSEcCtD
Ceftazidime—Headache—Vincristine—kidney cancer	0.000506	0.000801	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000503	0.000797	CcSEcCtD
Ceftazidime—Agranulocytosis—Doxorubicin—kidney cancer	0.000496	0.000786	CcSEcCtD
Ceftazidime—Hypotension—Capecitabine—kidney cancer	0.000492	0.000779	CcSEcCtD
Ceftazidime—Vomiting—Gemcitabine—kidney cancer	0.000487	0.000771	CcSEcCtD
Ceftazidime—Rash—Gemcitabine—kidney cancer	0.000483	0.000765	CcSEcCtD
Ceftazidime—Dermatitis—Gemcitabine—kidney cancer	0.000482	0.000764	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—kidney cancer	0.00048	0.00076	CcSEcCtD
Ceftazidime—Headache—Gemcitabine—kidney cancer	0.00048	0.00076	CcSEcCtD
Ceftazidime—Nausea—Vincristine—kidney cancer	0.00048	0.00076	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—kidney cancer	0.000477	0.000756	CcSEcCtD
Ceftazidime—Paraesthesia—Capecitabine—kidney cancer	0.000473	0.000748	CcSEcCtD
Ceftazidime—Hypersensitivity—Paclitaxel—kidney cancer	0.000472	0.000748	CcSEcCtD
Ceftazidime—Nausea—Gemcitabine—kidney cancer	0.000455	0.000721	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000454	0.00072	CcSEcCtD
Ceftazidime—Pruritus—Paclitaxel—kidney cancer	0.000454	0.000719	CcSEcCtD
Ceftazidime—Erythema multiforme—Doxorubicin—kidney cancer	0.000451	0.000715	CcSEcCtD
Ceftazidime—Pain—Capecitabine—kidney cancer	0.00045	0.000713	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—kidney cancer	0.000443	0.000702	CcSEcCtD
Ceftazidime—Diarrhoea—Paclitaxel—kidney cancer	0.000439	0.000695	CcSEcCtD
Ceftazidime—Angiopathy—Doxorubicin—kidney cancer	0.000433	0.000686	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—kidney cancer	0.000431	0.000683	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Capecitabine—kidney cancer	0.00043	0.000682	CcSEcCtD
Ceftazidime—Dizziness—Paclitaxel—kidney cancer	0.000424	0.000672	CcSEcCtD
Ceftazidime—Urticaria—Capecitabine—kidney cancer	0.000418	0.000662	CcSEcCtD
Ceftazidime—Abdominal pain—Capecitabine—kidney cancer	0.000416	0.000659	CcSEcCtD
Ceftazidime—Body temperature increased—Capecitabine—kidney cancer	0.000416	0.000659	CcSEcCtD
Ceftazidime—Vomiting—Paclitaxel—kidney cancer	0.000408	0.000646	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—kidney cancer	0.000407	0.000645	CcSEcCtD
Ceftazidime—Rash—Paclitaxel—kidney cancer	0.000404	0.00064	CcSEcCtD
Ceftazidime—Dermatitis—Paclitaxel—kidney cancer	0.000404	0.00064	CcSEcCtD
Ceftazidime—Headache—Paclitaxel—kidney cancer	0.000402	0.000636	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—kidney cancer	0.000392	0.00062	CcSEcCtD
Ceftazidime—Hypersensitivity—Capecitabine—kidney cancer	0.000388	0.000614	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—kidney cancer	0.000382	0.000605	CcSEcCtD
Ceftazidime—Nausea—Paclitaxel—kidney cancer	0.000381	0.000603	CcSEcCtD
Ceftazidime—Pruritus—Capecitabine—kidney cancer	0.000372	0.00059	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—kidney cancer	0.000372	0.000589	CcSEcCtD
Ceftazidime—Convulsion—Doxorubicin—kidney cancer	0.00036	0.00057	CcSEcCtD
Ceftazidime—Diarrhoea—Capecitabine—kidney cancer	0.00036	0.00057	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000351	0.000557	CcSEcCtD
Ceftazidime—Dizziness—Capecitabine—kidney cancer	0.000348	0.000551	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—kidney cancer	0.000339	0.000537	CcSEcCtD
Ceftazidime—Vomiting—Capecitabine—kidney cancer	0.000335	0.00053	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—kidney cancer	0.000333	0.000527	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—kidney cancer	0.000332	0.000526	CcSEcCtD
Ceftazidime—Rash—Capecitabine—kidney cancer	0.000332	0.000526	CcSEcCtD
Ceftazidime—Dermatitis—Capecitabine—kidney cancer	0.000331	0.000525	CcSEcCtD
Ceftazidime—Headache—Capecitabine—kidney cancer	0.00033	0.000522	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—kidney cancer	0.000329	0.000522	CcSEcCtD
Ceftazidime—Hypotension—Doxorubicin—kidney cancer	0.000317	0.000502	CcSEcCtD
Ceftazidime—Nausea—Capecitabine—kidney cancer	0.000313	0.000495	CcSEcCtD
Ceftazidime—Paraesthesia—Doxorubicin—kidney cancer	0.000305	0.000482	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000293	0.000464	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—kidney cancer	0.00029	0.000459	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000277	0.000439	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—kidney cancer	0.000269	0.000427	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—kidney cancer	0.000268	0.000425	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—kidney cancer	0.000268	0.000425	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—kidney cancer	0.00025	0.000396	CcSEcCtD
Ceftazidime—Pruritus—Doxorubicin—kidney cancer	0.00024	0.00038	CcSEcCtD
Ceftazidime—Diarrhoea—Doxorubicin—kidney cancer	0.000232	0.000368	CcSEcCtD
Ceftazidime—Dizziness—Doxorubicin—kidney cancer	0.000224	0.000355	CcSEcCtD
Ceftazidime—Vomiting—Doxorubicin—kidney cancer	0.000216	0.000342	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—kidney cancer	0.000214	0.000339	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—kidney cancer	0.000214	0.000338	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—kidney cancer	0.000212	0.000337	CcSEcCtD
Ceftazidime—Nausea—Doxorubicin—kidney cancer	0.000201	0.000319	CcSEcCtD
